<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This Phase II study evaluated darbepoetin alfa (<z:mp ids='MP_0000273'>DA</z:mp>) in 24 patients with predominantly low or intermediate-1 risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Intra-patient dose escalation of <z:mp ids='MP_0000273'>DA</z:mp> was undertaken in three 6-week dose cohorts until a major erythroid response was achieved: 4.5 mcg/kg/week, 9 mcg/kg/week, and 9 mcg/kg/week plus granulocyte-colony stimulating factor (G-CSF) 2.5 mcg/kg twice weekly </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) commenced <z:mp ids='MP_0000273'>DA</z:mp> at 9 mcg/kg/week </plain></SENT>
<SENT sid="3" pm="."><plain>The weight-based dosing regimen translated into a median starting <z:mp ids='MP_0000273'>DA</z:mp> dose of 390 mcg/week </plain></SENT>
<SENT sid="4" pm="."><plain>Erythroid responses were observed in 16/24 patients (67%; 12 major and 4 minor), with a median response duration of 11 months in major responders </plain></SENT>
<SENT sid="5" pm="."><plain>Addition of G-CSF generated a major erythroid response in 7/15 patients (47%) who suboptimally responded to <z:mp ids='MP_0000273'>DA</z:mp> alone </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0000273'>DA</z:mp> was well tolerated, except for worsening of baseline mild <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> in one patient with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>IPSS score &lt;0.5 and RBC transfusions &lt;2 units/month increased the probability of an erythroid response </plain></SENT>
<SENT sid="8" pm="."><plain>A minority of subjects (12%) developed low-level non-neutralizing anti-<z:mp ids='MP_0000273'>DA</z:mp> antibodies </plain></SENT>
<SENT sid="9" pm="."><plain>Our data indicate that weekly weight-based dosing of <z:mp ids='MP_0000273'>DA</z:mp>, with the addition of G-CSF in selected individuals, can be an effective erythropoietic option in a high proportion of lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>